| AIDS Budget Faces Reduction New York City's efforts to stem the spread of HIV/AIDS could shrink under the proposed cuts in the city budget, as the total number of new cases of the virus is down from four years ago. online.wsj.com |
The Skinny on Arena's Partnership With Japan's Eisai Ruthanne Williams Roussel submits:On July 1 Arena Pharmaceuticals (ARNA) announced a US marketing partnership for its late-stage obesity drug candidate lorcaserin with the US arm of Japan's Eisai, known for gastrointestinal drugs, among others. A well-attended conference call was held before market open, which will be archived on the company's web site for 30 days.Reasonable people may disagree whether this is the long hoped-for partnership with Big Pharma by one of the three small-pharma obesity drug developers, ARNA, Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), all of whom have drug candidates up for FDA review and approval within the next 6 months. While I personally would think of the top dozen or so companies by worldwide revenues when people say "Big Pharma" -- Pfizer (PFE) , GlaxoSmithKline (GSK), Roche et al. -- Eisai is certainly in or close to the top 20, depending on who's counting and over what period, and a muscular partner.Complete Story » seekingalpha.com |
Competitive Technologies: Short Squeeze Coming or Another Leg Down? David Greene submits:What is going on at Competitive Technologies, Inc. (AMEX:CTT) is an example of positive fundamentals being trumped by a mismanaged private placement. Ever since CTT announced a Private Placement to raise capital and that the AMEX was considering delisting if the company did not meet shareholder equity minimums, the stock has been understandably under pressure.Complete Story » seekingalpha.com |
Patty Loveless' DRIVE4COPD video - Video New drive4copd Ambassador Program Unites Celebrities and Fans in Nationwide Screening Contest feedproxy.google.com |
December Will Be Exciting for Up and Coming Corcept Pharmaceuticals Sheff Station submits:In December, the Phase 3 results for Corlux for the treatment of Cushing’s Syndrome are due out and investors have been showing an appetite for the stock as of late. This was evidenced by the unusual volume on Friday, which was a half-day for the equity markets. “Approximately 710,100 shares changed hands, a 970.6 percent increase over its 65-day average volume.” The analyst upgrades have been climbing since start of fall. In August, Global Securities initiated coverage on CORT with a buy rating and $5 price target. On Oct. 29th, Leerink Swann initiated coverage with an Outperform rating. On Nov. 17th, Piper Jaffray initiated coverage of CORT with an Overweight and a $7 target price.Complete Story » seekingalpha.com |